FeesSafety
Pluang+
Home/News Feed/AstraZeneca shares drop nearly 9% after heart drug trial fails main goal
AZN
$188.50
+$4.62 +2.51%

AstraZeneca shares drop nearly 9% after heart drug trial fails main goal

Market News
09 Jul 2026, 10:34 WIB
CNBC
View Source
Bearish
AstraZeneca shares drop nearly 9% after heart drug trial fails main goal

AstraZeneca's shares fell nearly 9% after its experimental heart drug, Wainua, failed to meet the primary goal in a late-stage trial. The drug aimed to reduce deaths and heart-related emergencies over 140 weeks for patients with a rare heart condition called transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The failure marks a significant setback for the British drugmaker, with shares hitting their worst day since March 2020. Investors will be watching closely for AstraZeneca's next steps following this trial result.

More News (AZN)

Regulatory review begins for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutated lung cancer in Europe and Japan

Regulatory review begins for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutated lung cancer in Europe and Japan

HUTCHMED and AstraZeneca have secured regulatory review acceptance in Europe and Japan for ORPATHYS (savolitinib) combined with TAGRISSO (osimertinib) to treat MET-driven EGFR-mutated non-small cell lung cancer (NSCLC). This follows a US FDA submissi...

Market News
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App